Oral semaglutide (Rybelsus, Novo Nordisk) lowered hemoglobin A1c more than empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) in a recently published open-label, head-to-head comparison of the type ...

Among diabetes drugs, GLP-1 receptor agonists and SGLT2 inhibitors were associated with greater reduction in the risk for Alzheimer’s disease (AD) than DPP-4 inhibitors, new research showed. “GLP-1 ...

A groundbreaking development in diabetes treatment reveals that SGLT-2 inhibitors significantly reduce dementia risk among type 2 diabetes patients. Recent research demonstrates these medications ...

The landscape of diabetes management is undergoing a remarkable transformation. Groundbreaking research has uncovered surprising cardiovascular benefits tied to modern medications, offering new hope ...

A large McGill University study has found that two classes of medications commonly prescribed for type 2 diabetes, both incretin-based, are associated with a reduced risk of dementia. Drawing on ...

Patterns differ among medication classes; potential mechanisms need more research ...

Add Yahoo as a preferred source to see more of our stories on Google. According to the WHO, more than 800 million people around the world have diabetes, with more than half of them not receiving ...

A new Northwestern Medicine study has shed light on how a class of diabetes drugs may protect the kidneys—not just by lowering blood sugar, but by triggering a molecular shift that dampens ...

When diabetes causes CKD, it’s sometimes called diabetic kidney disease. Elevated blood sugar levels that result from diabetes can damage the tiny blood vessels inside your kidneys. As a result, your ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Most people ...